NCT03861403 2023-11-30A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid TumorsLeap Therapeutics, Inc.Phase 1 Terminated10 enrolled
NCT03941262 2023-11-13Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional TherapyNKGen Biotech, Inc.Phase 1 Completed27 enrolled